Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that does not respond to endocrine therapy or human epidermal growth factor receptor 2 (HER2)-targeted therapies. Individuals with TNBC experience higher rates of relapse and shorter overall survival compared to patients wit...

Full description

Saved in:
Bibliographic Details
Published in:Sci Transl Med
Main Authors: Schafer, Johanna M., Lehmann, Brian D., Gonzalez-Ericsson, Paula I., Marshall, Clayton B., Beeler, J. Scott, Redman, Lindsay N., Jin, Hailing, Sanchez, Violeta, Stubbs, Matthew C., Scherle, Peggy, Johnson, Kimberly N., Sheng, Quanhu, Roland, Joseph T., Bauer, Joshua A., Shyr, Yu, Chakravarthy, Bapsi, Mobley, Bret C., Hiebert, Scott W., Balko, Justin M., Sanders, Melinda E., Liu, Phillip C.C., Pietenpol, Jennifer A.
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7427123/
https://ncbi.nlm.nih.gov/pubmed/32161105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aaw8275
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items